IN8bio Inc.

IN8bio Inc. (INAB) is a United States-based clinical-stage biopharmaceutical company focused on developing innovative gamma-delta T cell therapies for the treatment of cancer. The company's proprietary technology aims to harness the power of the patient's own immune system to target and eliminate cancer cells. IN8bio's research and development efforts are centered on creating novel immunotherapies designed to overcome the limitations of existing cancer treatments. By engineering and expanding gamma-delta T cells, IN8bio seeks to deliver targeted therapies that are both effective and well-tolerated. The company is committed to advancing its pipeline of product candidates through clinical trials, with the goal of providing new hope for patients battling aggressive and treatment-resistant cancers. IN8bio operates within the biotechnology sector, contributing to the advancement of cancer immunotherapy.